Jeweleeh H Yu, PA
Physician Assistant · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 2 carriers
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Plans that list them
18 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Jeweleeh H Yu’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Year by year
| 2020 | 14 | 60 | 70 | 1.13 | $6,290 | $1,245 |
| 2019 | 44 | 116 | 73 | 0.76 | $14,400 | $5,271 |
| 2017 | 52 | 199 | 76 | 1.06 | $23,140 | $7,105 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2019: 3 services
| Short return visit (20+ min) | 28 | $1,879 | $54 |
| Destruction of skin growth, 1-14 growths | 11 | $1,237 | $88 |
| New patient visit (30+ min) | 15 | $1,015 | $68 |
2017: 5 services
| Short return visit (20+ min) | 41 | $2,140 | $48 |
| Destruction of skin growth, 1-14 growths | 12 | $960 | $74 |
| Destruction of precancer skin growth, 1 growth | 22 | $810 | $37 |
| New patient visit (30+ min) | 11 | $753 | $68 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $307 | $4 |
Drugs they prescribed that Part D paid
$138,917
Pharmacies billed $138,917 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 401) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
327 generic and 74 brand-name prescriptions · $138,917 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Calcipotriene | 32 | $2,540 | $79 |
| Fluorouracil | 52 | $2,061 | $40 |
| Triamcinolone Acetonide | 39 | $960 | $25 |
| Clobetasol Propionate | 50 | $895 | $18 |
| Mupirocin | 21 | $337 | $16 |
See all 8 drugs
| Calcipotriene | 32 | $2,540 | $79 |
| Fluorouracil | 52 | $2,061 | $40 |
| Triamcinolone Acetonide | 39 | $960 | $25 |
| Clobetasol Propionate | 50 | $895 | $18 |
| Mupirocin | 21 | $337 | $16 |
| Hydrocortisone | 20 | $240 | $12 |
| Ketoconazole | 15 | $218 | $15 |
| Lorazepam | 13 | $12 | $1 |
Year by year
| 2024 | 401 | 165 | 0% (0) | 18% | $138,917 |
| 2023 | 412 | 172 | 0% (0) | 9% | $133,489 |
| 2022 | 275 | 135 | 0% (0) | 4% | $19,107 |
| 2021 | 46 | None | 0% (0) | 0% | $895 |
| 2020 | 21 | None | 0% (0) | 0% | $1,192 |
| 2019 | 60 | 15 | 0% (0) | None | $4,994 |
| 2018 | 87 | 15 | 0% (0) | 18% | $7,616 |
| 2017 | 264 | 39 | 0% (0) | 14% | $40,131 |
| 2016 | 76 | 20 | 0% (0) | None | $4,669 |
| 2015 | 76 | 44 | 0% (0) | 22% | $10,838 |
| 2014 | 32 | 15 | 0% (0) | None | $4,507 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Calcipotriene | 27 | $2,736 | $101 |
| Fluorouracil | 62 | $2,515 | $41 |
| Vectical | 14 | $2,140 | $153 |
| Clobetasol Propionate | 69 | $1,592 | $23 |
| Triamcinolone Acetonide | 41 | $1,140 | $28 |
| Tacrolimus | 11 | $741 | $67 |
| Doxycycline Monohydrate | 15 | $355 | $24 |
| Mupirocin | 20 | $255 | $13 |
| Hydrocortisone | 20 | $230 | $12 |
| Ketoconazole | 13 | $192 | $15 |
| Lorazepam | 13 | $31 | $2 |
2022: 8 drugs
| Fluorouracil | 57 | $3,825 | $67 |
| Calcipotriene | 26 | $2,883 | $111 |
| Triamcinolone Acetonide | 31 | $927 | $30 |
| Clobetasol Propionate | 22 | $842 | $38 |
| Ketoconazole | 14 | $219 | $16 |
| Duloxetine | 12 | $159 | $13 |
| Mupirocin | 11 | $142 | $13 |
| Lorazepam | 12 | $40 | $3 |
2021: 1 drug
| Lorazepam | 13 | $135 | $10 |
2019: 1 drug
| Bupropion Xl | 12 | $763 | $64 |
2018: 2 drugs
| Buspirone | 13 | $566 | $44 |
| Bupropion Xl | 14 | $508 | $36 |
2017: 7 drugs
| Latuda | 17 | $21,859 | $1,286 |
| Buspirone | 17 | $677 | $40 |
| Ketoconazole | 17 | $637 | $37 |
| Quetiapine | 20 | $412 | $21 |
| Trazodone | 25 | $92 | $4 |
| Lamotrigine | 13 | $73 | $6 |
| Topiramate | 16 | $63 | $4 |
2016: 1 drug
| Quetiapine | 11 | $239 | $22 |
2015: 2 drugs
| Ketoconazole | 14 | $775 | $55 |
| Triamcinolone Acetonide | 19 | $223 | $12 |
Money from drug and device companies
$232 in 2025
| 2025 | 5 | 6 | None | $232 |
| 2024 | 3 | 3 | None | $57 |
| 2023 | 5 | 9 | None | $189 |
| 2022 | 6 | 12 | None | $244 |
| 2021 | 9 | 37 | None | $696 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $111 | 1 payment
|
| Axsome Therapeutics | Auvelity | $43 | 2 payments
|
| Lundbeck | Rexulti | $30 | 1 payment
|
| Abbvie | Vraylar | $26 | 1 payment
|
| Bausch Health US | Aplenzin | $22 | 1 payment
|
See all 6 published payments
| Bausch Health US | Meals · 2025-12-22 | Aplenzin | $22 |
| Axsome Therapeutics | Meals · 2025-08-21 | Auvelity | $26 |
| Galderma Laboratories L.P. | Meals · 2025-07-24 | Nemluvio | $111 |
| Axsome Therapeutics | Meals · 2025-03-20 | Auvelity | $18 |
| Abbvie | Meals · 2025-02-19 | Vraylar | $26 |
| Lundbeck | Meals · 2025-01-16 | Rexulti | $30 |
See earlier years (2024, 2023, 2022, 2021)
2024: $57
| Lundbeck | Rexulti | $27 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $15 | 1 payment
|
| Abbvie | Vraylar | $14 | 1 payment
|
2023: $189
| Abbvie | Vraylar | $84 | 4 payments
|
| Bausch Health US | Aplenzin | $36 | 2 payments
|
| Axsome Therapeutics | Auvelity | $29 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $20 | 1 payment
|
2022: $244
| Alkermes | Aristada | $84 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $63 | 3 payments
|
| Bausch Health US | Aplenzin | $30 | 2 payments
|
| Iti | Caplyta | $29 | 1 payment
|
| Alfasigma USA | None | $21 | 1 payment
|
| Abbvie | Vraylar | $17 | 1 payment
|
2021: $696
| AbbVie | Vraylar | $243 | 15 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $175 | 9 payments
|
| Iti | Caplyta | $99 | 3 payments
|
| Sunovion Pharmaceuticals | Latuda | $44 | 3 payments
|
| Alkermes | Aristada | $41 | 2 payments
|
| Adlon Therapeutics L.P. | Adhansia Xr | $35 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $23 | 1 payment
|
| Lundbeck | Rexulti | $21 | 1 payment
|
| Merck Sharp & Dohme | Belsomra | $15 | 1 payment
|
Professional record
- NPI
- 1659713329
- Licence
- CA PA23090
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant, medical (363AM0700X)
- Mailing address
- Po Box 210271, San Francisco, CA, 94121
- NPI first listed
- 2013-07-23
- NPI last updated
- 2022-06-02
- NPI record certified
- 2022-06-02
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.